COMMUNIQUÉS West-GlobeNewswire

-
Nova Leap Health Corp. to Discuss Record 2023 Results and Present at the Planet MicroCap Showcase
22/04/2024 - 14:25 -
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
22/04/2024 - 14:05 -
Amarin Announces Results of Annual General Meeting of Shareholders
22/04/2024 - 14:00 -
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
22/04/2024 - 14:00 -
DLH to Announce Fiscal 2024 Second Quarter Financial Results
22/04/2024 - 14:00 -
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
22/04/2024 - 14:00 -
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
22/04/2024 - 14:00 -
Celularity Inc. to Host Investor and Analyst Research & Development Day
22/04/2024 - 14:00 -
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
22/04/2024 - 14:00 -
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
22/04/2024 - 14:00 -
Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024
22/04/2024 - 14:00 -
SS Innovations International Announces Q1 2024 Company Updates
22/04/2024 - 14:00 -
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
22/04/2024 - 14:00 -
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
22/04/2024 - 14:00 -
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
22/04/2024 - 14:00 -
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
22/04/2024 - 14:00 -
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
22/04/2024 - 13:51 -
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
22/04/2024 - 13:30 -
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
22/04/2024 - 13:30
Pages